Iole Airoldi, Italy
Ahmed Alissa, Saudi Arabia
Tag Anbar, Egypt
Laila Benzekri, Morocco
Piergiacomo Calzavara Pinton, Italy
Caio Castro, Brazil
Tania Cestari, Brazil
Andrea Diociaiuti, Italy
Viktoria Eleftheriadou, UK
Khaled Ezzedine, France
Pearl Grimes, USA
Iltefat Hamzavi, USA
John E. Harris, USA
Hee Young Kang, Korea
Ichiro Katayama, Japan
Boon Kee Goh, Singapore
Prasad Kumarasinghe, Australia
Eric Lan, Taiwan

Caroline I. Le Poole, USA
Giovanni Leone, Italy
Henry W. Lim, USA
Torello Lotti, Italy
Harvey Lui, Canada
Giuseppe Monfrecola, Italy
Silvia Moretti, Italy
Luigi Naldi, Italy
Iria Neri, Italy
Amit G. Pandya, USA
Davinder Parsad, India
Noufal Raboobee, South Africa
Richard A. Spritz, USA
Tamio Suzuki, Japan
Alain Taieb, France
Nanja Van Geel, Belgium
Leihong Flora Xiang, China
Yowen Zhou, Canada
The conference (n° 172893) is accredited by the Provider “Quality Congress”. The following health professionals will obtain 16 CME credits:

> BIOLOGISTS
> PSYCHOTHERAPISTS
> PSYCHOLOGISTS
> ALLERGOLOGISTS
> DERMATOLOGISTS
> PLASTIC SURGEONS
> CLINICAL PATHOLOGISTS
> ANALYTICAL CHEMISTS

To receive your CME credits you are required to fill the evaluation questionnaire and give it back to the Conference Office.
08.30 - 09.00 Welcome with coffee / Installation of posters

09.00 - 09.15 Introduction by the Chairs Mauro Picardo and Alain Taieb: Facing challenges in vitiligo research

09.15 - 09.45 Introductory lecture presented by Harvey Lui Richard Spritz: Key pathways identified by genetic studies

09.45 - 11.40 Session 1
New insights from basic and translational research

09.45 - 10.00 Introduction by John Harris

10.00 - 11.30 Oral presentations chosen from submitted abstracts:

- **Jacquemin Clément**  HSP70 enhances the production of interferon alpha by plasmacytoid dendritic cells: relevance for vitiligo pathogenesis.  
  Rambert Jérôme, Guillet Stéphanie, Ezzedine Khaled, Taieb Alain, Boniface Katia, Seneschal Julien (France)

- **Manga Prashiela**  A role for the unfolded protein response in the pathogenesis of vitiligo.  
  Seth J. Orlow Omotayo, A. Arowojolu (NY United States)

- **Harris John**  A CXCR3 depleting antibody removes autoreactive T cells and reverses depigmentation in a mouse model of vitiligo.  
  Jillian Richmond, Elizabeth Masterjohn, Ruiyin Chu, Jennifer Tedstone, Michele Youd (MA United States)

- **Kovacs Daniela**  Non lesional vitiligo skin: dermal influences.  
  Emanuela Bastonini, Monica Ottaviani, Emilia Migliano, Carlo Kota, Maria Lucia Dell’Anna, Mauro Picardo (Italy)

- **Dell’Anna Maria Lucia**  The mitochondrial metabolic aspects in vitiligo.  
  Daniela Kovacs, Simone Mirabile, Maria Rosaria Ricciardi, Monica Ottaviani, Emanuela Bastonini, Barbara Bellei, Carlo Kota, Agostino Tafuri, Mauro Picardo (Italy)

- **Bordignon Matteo**  MIA (melanoma inhibitory activity) is able to induce vitiligo in an “in-vivo” mice model by direct injection in the tail.  
  Roberto Luisetto, Marialuisa Valente, Marny Fedrigo, Chiara Castellani, Annalisa Angelini (Italy)
Suzuki Tamio Rhododendrol-induced leukoderma analyzed with a model mouse. 
Yuko Abe, Ken Okamura, Yutaka Hozumi, Takahiro Kunisada, Shosuke Ito, Kazumasa Wakamatsu (Japan)

11.30 - 11.40 Conclusions by Hee Young Kang

11.40 - 12.00 Coffee break + poster viewing

12.00 - 12.30 Invited lecture presented by Leihong Flora Xiang 
Ralf Paus: Hair follicle melanocytes and their stem cells as a repigmentation resource

12.30 - 12.45 Rome San Gallicano workshop II on outcome measures: preliminary data 
Alain Taieb, Nanja Van Geel, Reinhart Speeckaert, Viktoria Eleftheriadou, Mauro Picardo

12.45 - 14.00 Lunch

14.00 - 16.10 Session 2 
Outcome research part 1: Prognosis/biomarkers

14.00 - 14.15 Introduction by Amit Pandya

14.15 - 16.00 Oral presentations chosen from submitted abstracts:

- Speeckaert Reinhart Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo. 
  Nanja van Geel (Belgium)

- Abdallah Marwa Serum CXCL 10 as activity marker for vitiligo. 
  Medhat El-Mofty, Tag Anbar, Samia Esmat, Dalia Bassiouny, Dalia Abdel-Halim, Mona Ibrahim (Egypt)

  Hinojosa, Amit G. Pandya (TX United States)

- Harris John Blistering lesional skin in vitiligo patients reveals sensitive and specific biomarkers of disease activity. 
  James Strassner, Mehdi Rashighi, Maggi Ahmed Refat, Jillian Richmond (MA United States)
Boniface Katia  Deciphering the role of skin effector and resident memory T cells in vitiligo.
Nesrine Boukhedouni, Clément Jacquemin, Jérôme Rambert, Alain Taieb, Khaled Ezzedine, Julien Seneschal (France)

Yang Lingli  Dysregulation of circulating T cells anergy might be involved in autoimmune disorder of vitiligo.
Atsushi Tanemura, Takayoshi Morita, Kenichi Kato, Atsushi Tanaka, Shimon Sakaguchi, Ichiro Katayama (Japan)

Kaushik Hitaishi  Functional RNomics of miR-2909 in Human Non-Segmental Vitiligo Skin.
Davinder Parsad, Deepak Kaul (India)

Piquero-Casals Jaime  The innate immune receptor CD91 and levels of erythrocyte malonyldialdehyde (MDA) as activity markers of vitiligo.
Laura Martinez-Martinez, Eduardo Rozas, Maria Lozano-Rabell, Luis Puig, Cándido Juárez, Agustín Alomar (Spain)

16.00 - 16.10 Conclusions by Nanja Van Geel and Reinhart Speeckaert

16.10 - 17.15 Coffee break + Poster walk 1 (Leaders: Lionel Larue, Samia Esmat, Luigi Naldi)

17.15 - 18.55 Session 3
Outcome research part 2: Assessment/scoring

17.15 - 17.30 Introduction by Iltefat Hamzavi

17.30 - 18.45 Oral presentations chosen from submitted abstracts:

Van Geel Nanja  Responsiveness of the Vitiligo extent score (VES) to Vitiligo changes and the need for a VESplus to assess repigmentation.
Janny E Lommerts, Marcel Bekkenk, Cecilia AC Prinsen, Viktoria Eleftheriadou, Alain Taieb, Mauro Picardo, Khaled Ezzedine, Reinhart Speeckaert (Belgium, The Netherlands, United Kingdom, France, Italy)

Coias Jennifer  Validation of the Vitiligo Disease Activity Index.
Amit Pandya (TX United States)
> **Jung Min Bae**  Classification of non-segmental facial vitiligo: A cluster analysis of 473 patients.  
*Yu Seok Jung Jung, Hanna Lee, Ji Hun Park, Seung-Kyung Hann (South Korea)*

> **Shalaby Suzan**  Changes in matrix metalloproteinases during NB-UVB induced pigmentation in cases of active vitiligo.  
*Tag Anbar, Medhat El Mofty, Samia Esmat, Wedad Mostafa, Marwa Abdalah, Hoda Rasheed (Egypt)*

> **Wright Evan J.**  Immunological profile of inflammatory cells in the skin of patients with vitiligo undergoing treatment.  
*Amit Pandya, Jorge Hinojosa, James Strassner, John Harris (TX, MA United States)*

18.45 - 18.55  Conclusions by Khaled Ezzedine

18.55 - 19.15  General discussion led by Mauro Picardo and Alain Taieb

20.00 - 22.00  Social Event
08.30 - 09.00 Welcome with coffee

09.00 - 09.10 Update by the Chairs Mauro Picardo and Alain Taieb

09.10 - 09.40 Invited lecture presented by Pearl Grimes
Caroline Le Poole: New perspectives in vitiligo therapies

09.40 - 11.40 Session 4
Management of vitiligo: combining physicians’ and patients’ perspectives

09.40 - 09.55 Introduction by Davinder Parsad

09.55 - 11.35 Oral presentations chosen from submitted abstracts:

> Anbar Tag  Motor tics in patients diagnosed with vitiligo: relationship to depressive and anxiety symptoms.
Amal Abdel-Rahman, Nashat Abdel-Fadeel, A El-Sherbiny, Ibrahim Kharboush, Ahmed Sanad (Egypt)

> Cestari Tania  Quality of Life Impairment in Children and Adults with Vitiligo: a cross-sectional study based on dermatology-specific and disease-specific quality of life instruments.
Juliana Catucci Boza, Natalia Giongo, Priscilla Machado, Roberta Horn, Amanda Fabbrin (Brazil)

Janny E Lommerts, Marcel Bekkenk, Cecilia AC Prinsen, Viktoria Eletheriadou, Alain Taieb, Mauro Picardo, Khaled Ezzedine, Albert Wolkerstorfer, Reinhart Speeckaert (Belgium, The Netherlands, United Kingdom, France, Italy)

> Alissa Ahmed  Practical Tips in Vitiligo (Saudi Arabia)

> Eid Amira  Evaluation of factors influencing objective assessment of skin color by colorimetry.
Tag Anbar, Mohamed Anbar (Egypt)

> Speeckaert Reinhart  The role of S100B in the pathogenesis of vitiligo.
Nanja van Geel (Belgium)
Debdeep Mitra  A randomized control trial to study of efficacy of cultured versus non cultured melanocyte transfer in the surgical management of stable vitiligo. (India)

Hee Young Kang  Efficacy of continuous vs. cyclic on-off excimer laser treatment for vitiligo: A prospective randomized controlled non-inferiority trial.
Jung Min Bae, Hee Young Kang (South Korea)

11.35 - 11.45 Conclusions by Nicolle Maquignon

11.45 - 12.00  Coffee break + poster view

12.00 - 12.30 Invited lecture presented by Ichiro Katayama
Eddy HC. Wang (Columbia University Medical Center of New York)
Treatment with JAK inhibitors: prevention and reversal of clinical manifestations.

12.30 - 13.45 Lunch

13.45 - 15.50 Session 5
Clinical and experimental studies

13.45 - 14.00 Introduction by Thierry Passeron

14.00 - 15.40 Oral presentations chosen from submitted abstracts:

> Erf Gisela  Spontaneous autoimmune vitiligo in the Smyth chicken: relevant intermediate model for pre-clinical research.
Daniel Falcon (AR United States)

> Ichihashi Masamitsu  Protective effects of platinum and palladium nanoparticles on human keratinocytes via AHR and NRF2 activation: Implication in vitiligo therapy.
Gaku Tsuji, Takakazu Shibata, Hideya Ando, Yorihiro Yamamoto, Yukiko Minamiyama, Masutaka Furue (Japan)

> Kotobuki Yorihisa  Histopathological comparison with anti-PD-1 antibody-induced leukoderma, vitiligo and Rhododenol-induced leukoderma.
Atsushi Tanemura, Noriko Arase, Fei Yang, Lingli Yang, Mari Wataya-Kaneda, Ichiro Katayama (Japan)
Raboobee Noufal  Epidermal cell suspension prepared inside suction blisters for transplantation in vitiligo.  
Musarrath Raboobee (South Africa)

Benzekri Laila  First transplantation of basal cell layer suspension using a dermarolling system in vitiligo: A preliminary clinical study of 5 cases.  
Yvon Gauthier (Morocco)

Lommerts Annelies  The role of phototherapy in the surgical treatment of vitiligo: a systematic review.  
Marcel Bekkenk, Menno de Rie, Albert Wolkerstorfer (The Netherlands)

Seneschal Julien  Vitiligoid lesions occurring under anti-PD-1 therapies are clinically and biologically distinct from vitiligo.  
Katia Boniface, Clément Jacquemin, Jérôme Rambert, Alain Taïeb, Caroline Dutriaux, Sorilla Prey (France)

Lui Harvey  Novel autofluorescence biomarkers of vitiligo  
Jianhua Zhao, Sunil Kalia, Mohammed Al Jasser, Soodabeh Zandi, Nikiforos Kollias, Vincent Richer, Haishan Zeng (Canada)

15.40 - 15.50  Conclusions by Bon Kee Goh

15.50 - 17.00  Coffee break + Poster walk 2 (Leaders: Laila Benzekri, Tamio Suzuki, Silvia Moretti, Prasad Kumarasinghe)

17.00 - 18.20  Session 6  
New therapeutic targets

17.00 - 17.10  Introduction by Julien Seneschal

17.10 - 18.10  Oral presentations chosen from submitted abstracts:

  > Harris John  T regulatory cells follow chemokine signals in vitiligo to co-localize with autoreactive T cells and control their numbers in the skin.  
Kingsley Essien, Jillian Richmond, Mehdi Rashighi (MA United States)

  > EL-Hawary Marwa  Platelet Rich Plasma in the treatment of Vitiligo;  
A comparative clinical study.  
Eman Shaarawy, Randa Aguizy (Egypt)

  > Van Geel Nanja  First randomized controlled trial to compare laser (755NM) and cryotherapy as depigmentation tratments for vitiligo.  
Emily Van Hoeylandt, Hilde Lapeere, Barbara Boone, Evelien Verhaeghe, Sofie De Schepper, Reinhart Speeckaert (Belgium)
> Babino Graziella  UVA 1 Laser in the Treatment of Vitiligo. 
_Ester Del Duca, Maria Esposito, Alessandro Giunta, Rosita Saraceno, Luca Bianchi, Steven Nisticò (Italy)_

> Pacifico Alessia  Combined treatment of narrow band UVB (NB UVB) phototherapy and oral polypodium leucomotos (PL) extract versus NB UVB phototherapy alone in the treatment of patients with vitiligo. 
_Marco Ardigò, Paolo Iacovelli, Andrea Paro Vidolin, Giovanni Leone (Italy)_

18.10 - 18.20  Conclusions by Eric Lan and Giovanni Leone

18.20 - 19.30  Session 7
Clinical reports

18.20 - 18.30  Introduction by Agustin Alomar

18.30 - 19.20  Oral presentations chosen from submitted abstracts:

> Castro Caio  A case series report of association between bilateral segmental vitiligo and lichen striatus: An expression of mosaicism? 
_St Louyse Dumas (Brazil)_

> Katayama Ichiro  Valsartan/hydrochlorothiazide compound drug-induced photoleukomelanoderma developed in vitiligo. Comparative immunohistochemical study with special reference to IL17A. 
_Natsuko Shimada, Emi Ono, Aya Takahashi, Aya Tanaka, Atsushi Tanemura (Japan)_

> Gupta Monisha  Camouflage - an underutilised option in the management of pigmentary disorders. (Australia)

> Anbar Tag  The presence of depigmented rim around the successful grafting of vitiligo lesions: A case series. 
_Ahmed Alissa, Mohamed Anbar (Egypt, Saudi Arabia)_

19.20 - 19.30  Conclusions by Henry Lim

19.30 - 20.00  General discussion and concluding remarks by Mauro Picardo and Alain Taieb

20.00  Aperitif and closing party
9. **MELANOCYTE NADPH OXIDASE ACTIVATION INDUCED BY KERATINOCYTE-DERIVED ROS**  
Victoria Barygina, Amanda Mannucci, Roberta Colucci, Niccolò Taddei, Torello Lotti, Silvia Moretti, Claudia Fiorillo (Italy)

10. **AUTOLOGOUS MELANOCYTE-KERATINOCYTE SUSPENSION IN NSV; IS SUPPLEMENTATION OF THE SUSPENSION MEDIUM BENEFICIAL**  
Dalia Bassiouny, Bakr ElZawahry, Samia Esmat, Marwah Saleh, Dalia Abdelhalim, Rehab Hegazy, Heba Gawdat (Egypt)

11. **EFFECT OF FRACTIONAL CARBON DIOXIDE LASER ON REPIGMENTATION OF ACRAL VITILIGO AFTER NON CULTURED EPIDERMAL CELL SUSPENSION (NCES) GRAFTING; AN IMMUNOHISTOCHEMICAL STUDY**  
Samia Esmat, Magda Assaf, Dina Kadry, Adly Marwa, Ghada El Hanafy, Heba Saad, Marwa El Hawary (Egypt)

12. **INSIGHT INTO THE MOLECULAR PATHWAYS OF A PGE2 ANALOGUE IN REGULATING SKIN PIGMENTATION**  
Enrica Flori, Emanuela Bastonini, Isabella Coletta e Alessandra Alisi, Lorenzo Polenzani, Mauro Picardo (Italy)

14. **MAST CELL ACTIVATION PROMOTES POSSIBLE TRANSIENT HYPERMELANOSIS OF THE PERILESIONAL SKIN IN RHODODENDRON INDUCED-LEUKODERMA**  
Ichiro Katayama, Aya Takahashi, Fei Yang, Lingli Yang, Noriko Arase, Atsushi Tanemura, Mari Kaneda (Japan)

15. **FIBROBLAST DERIVED CLUSTERIN INHIBITS MELANOGENESIS VIA TGF-β SIGNALING**  
Jiun Lee, Misun Kim, Hee Young Kang, Tae Jun Park (South Korea)

17. **ROLE OF THE DECREASED RELEASE OF KERATINOCYTE GROWTH FACTOR IN THE PATHOGENESIS OF VITILIGO HYPO-PIGMENTATION**  
Flavia Persechino, Monica Nanni, Francesca Belleudi, Antonella Tammaro, Severino Persechino, Maria Rosaria Torrisi (Italy)

18. **A SHORTER LIFE SPAN AND ITS EXTENSION BY PAPLAL, NANOPARTICLES OF PLATINUM AND PALLADIUM, OF CULTURED MELANOCYTES OBTAINED FROM UNINVOLVED SKIN OF A VITILIGO PATIENT**  
Hideya Ando, Satoshi Yoshimoto, Moemi Yoshida, Takakazu Shibata, Masamitsu Ichihashi (Japan)
Session 2 - Outcome research part 1: Prognosis/biomarkers

27. EXPLORING VITILIGO RISK FACTORS IN KAZAKH PATIENTS
   Alma Aimoldina, Gulnar Batpenova, Togzhan Algazina (Kazakhstan)

28. SERUM LEVEL AND TISSUE EXPRESSION OF SYNTENIN 2 RECEPTOR IN VITILIGO PATIENTS AND THEIR CORRELATION WITH DISEASE PATTERN, ACTIVITY AND SEVERITY
   Mona Atwa, Rabab Elgenedy, Hanaa Mohamed, Nader Ismail, Sahar Mohamed, Noha Kamel (Egypt)

29. MELATONIN CONCENTRATION IN THE BLOOD AND PECULIARITIES OF CYTOKINE STATUS IN PATIENTS WITH VITILIGO AND STRESS IN ANAMNESIS
   Nino Tsiskarishvili Junior, Alexander Katsitadze, Nino Tsiskarishvili, Tsiskari Tsiskarishvili (Georgia)

30. EXPRESSION OF STEM CELL FACTOR (SCF) AND ITS RECEPTOR C-KIT IN VITILIGO EPIDERMIS
   Dorota Wilamowska- Kokoszko, Karolina Lukasik, Jacek Szepietowski, Dariusz J. Skarżyński, Waldemar Placek (Poland)

31. DYNAMIC VISUALIZATION OF DENDRITIC CELLS IN THE SKIN FROM PATIENTS WITH VITILIGO OR RHODODENDROL-INDUCED LEUKODERMA
   Fei Yang, Lingli Yang, Atsushi Tanemura, Mari Wataya-Kaneda, Ichiro Katayama (Japan)
Session 3 - Outcome research part 2: Assessment/scoring

38. THE EFFECTIVE POTENTIAL OF REFLECTANCE CONFOCAL MICROSCOPY IN THE DIAGNOSIS OF HYPOPIGMENTED LESIONS OF THE SKIN
Marco Ardigò, Paolo Iacovelli, Alessia Pacifico, Marina Agozzino, Mauro Picardo (Italy)

39. PREDICTIVE FACTORS OF THYROID DISEASES IN VITILIGO
Majda Askour, Syrine Hamada, Yasmina Ouidan, Badredine Hassam, Laila Benzekri (Morocco)

40. QUANTIFYING VITILIGO SEVERITY THROUGH DIGITAL IMAGE ANALYSIS
Letizia Gionfrida, AdaWai Kin Kong, Arfika Nurhudatiana, Steven Thng Tien Guan (Singapore)

41. NOVEL IMAGING AND QUANTIFICATION METHODS FOR THE EVALUATION OF DISEASE SEVERITY IN VITILIGO AND CHEMICAL LEUKODERMA
Masahiro Hayashi, Ken Okamura, Yuta Araki, Yuko Abe, Yutaka Hozumi, Masukazu Inoie, Tamio Suzuki (Japan)

42. ANALYSIS OF SYMMETRICITY IN THE THREE DIFFERENT (SAGITTAL, TRANSVERSE AND FRONTAL) PLANES IN GENERALIZED NON SEGMENTAL VITILIGO
Rehab Hegazy, Tag Anbar, Khaled Ezzedine, Rania Abdel Hay, Samia Esmat, Heba Diab, Mohammed Anbar (Egypt)

43. THE UTILITY OF PERFORMING ROUTINE BLOOD INVESTIGATIONS FOR ASSOCIATED AUTOIMMUNE DISEASE IN PATIENTS WITH NON-SEGMENTAL VITILIGO IN SOUTH AFRICA
Suretha Kannenberg (South Africa)

44. MAY THE PLASMATIC ANTIOXIDANT CAPACITY ASSOCIATED WITH DERMOSCOPIC OBSERVATION BE A USEFUL PARAMETER TO VALUE THE REPIGMENTATION IN PATIENTS WITH VITILIGO
Marco La Vecchia, Giuseppe Pistone, Maria Rita Bongiorno (Italy)

45. EFFECT OF DIFFERENT TYPES OF THERAPEUTIC TRAUMA ON VITILIGO LESIONS
Heba Mashaly, Medhat El Mofty, Samia Essmat, Nahla Hunter, Sarah Ibrahim, Olfat Shaker (Egypt)

46. THE VITILIGO WEB DATA BASE
Julien Seneschal, Khaled Ezzedine, Nanja Van-Geel, Mauro Picardo, Alain Taieb (France, Belgium, Italy)
47. DEVELOPMENT AND VALIDATION OF A DISEASE ACTIVITY SCORE FOR VITILIGO
Nanja van Geel, Laura Mertens, Albert Wolkerstorfer, Janny E. Lommerts, Cecilia AC Prinsen, Viktoria Eleftheriadou, Alain Taieb, Mauro Picardo, Khaled Ezzedine, Marcel Bekkenk, Reinhart Speeckaert (Belgium, The Netherlands, United Kingdom, France, Italy)

Session 4 - Management of vitiligo: combining physicians’ and patients’ perspectives

56. ASSOCIATION OF GENITAL VITILIGO WITH SEXUAL QUALITY OF LIFE
Marwa Abdallah, Sahar El-Sayed Youssef, Mahmoud El-Habiby, Karim Abdel Mohsen (Egypt)

58. THE TREATMENT OF VITILIGO PATIENTS AND NEW TREATMENT APPROACHES
St Zehra Bahar GEY (Bulgaria)

59. REPIGMENTATION OF VITILIGO LESIONS IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE
Jorge A. Hinojosa, Amit G. Pandya (TX United States)

60. QUALITY OF LIFE IN PATIENTS WITH VITILIGO ACCORDING TO GENDER AND AGE OF ONSET
Jorge A. Hinojosa, Ella Miller, Amit G. Pandya (TX United States)

61. TRIALS AND RESULTS OF VARIOUS NOVEL THERAPIES FOR INTRACTABLE CASES OF VITILIGO VULGARIS
Takakazu Shibata (Japan)

62. IDENTIFYING KEY COMPONENTS FOR A PSYCHOLOGICAL INTERVENTION FOR PEOPLE WITH VITILIGO – OUTCOME OF TWO FOCUS GROUPS
Liz Steed, A Ahmed, E Burden-Teh, R Shah, S Sanyal, S Dowey, M Whitton, J Batchelor, A Bewley (United Kingdom)

64. AN INCREASED RISK OF COMORBID RHEUMATIC DISORDERS IN VITILIGO PATIENTS: A NATION WIDE POPULATION-BASED STUDY
Chong Won Choi, Sung Hye Eun, Kwang Hyun Choi, Jung Min Bae (South Korea)

65. VITILIGO TREATMENT RECOMMENDATIONS: WHERE ARE WE NOW?
Andrija Stanimirović, Maja Kovacevic, Mirna Situm (Croatia)
Session 5 - Clinical and experimental studies

16. **LIGHT-INDEPENDENT PRO-INFLAMMATORY AND PRO-OXIDANT EFFECTS OF PURIFIED HUMAN HAIR MELANINS ON KERATINOCYTE CELL CULTURES**
   Serena Lembo, Alessandra Napolitano, Roberta Di Caprio, Lucia Panzella, Raffaella Micillo, Anna Balato, Giuseppe Monfrecola (Italy)

74. **SUCCESS OF EXCIMER LIGHT IN THE TREATMENT OF VITILIGO LESIONS WHICH STOPPED IMPROVEMENT WHILE ON NBUVB THERAPY**
   Mohamed Anbar, Tag Anbar (Egypt)

75. **COMPARISON OF 311-NM TI: SAPPHIRE LASER VS. 308-NM EXCIMER LASER TREATMENT FOR VITILIGO: A PROSPECTIVE RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL**
   Jung Min Bae, Sung Hye Eun, Hanna Lee, Ji Hae Lee, Gyong Moon Kim (South Korea)

76. **EVALUATING INSULIN RESISTANCE AND THE RISK FACTORS FOR CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITH VITILIGO: A CONTROLLED STUDY**
   Tania Ferreira Cestari, Carla Corrêa Martins, Natalia Piccinini Giongo, Roberta Horn, Amanda Rodrigues Fabbrin, Roberta Granja Machado, Juliana Catucci Boza (Brazil)

77. **EVALUATION OF CHOROIDAL THICKNESS IN THE EYE OF VITILIGO PATIENTS**
   Serkan Demirkan, Zafer Onaran, Ozgur Gunduz, Fatma Ozkal, Guzin Samav, Ayse Anil Karabulut (Turkey)

78. **A NEW SIMPLE METHOD FOR RECIPIENT SITE PREPARATION USING ELECTRO-DISSECTION DURING EPIDERMAL GRAFT PROCEDURE IN ACRAL VITILIGO SURGICAL TREATMENT**
   Hasan El-Fakahany, Walid Medhat, Hamza Abdel-Raouf (Egypt)

80. **VITILIGO 50 SHADES OF GRAY COME TO AN END! THE EMERGENCE OF PSEUDOCATALASE**
   Medhat Abdel Malek (Jordan)

81. **AUDIOLOGICAL ABNORMALITY AND VITILIGO**
   Giannicola Iannella, Dario D15idona, Liliana Guerra, Biagio Didona, Giuseppe Magliulo (Italy)
87. POSSIBLE BENEFIT OF TOCOTRIENOLS IN VITILIGO TREATMENT.
Stefania Briganti, Michele Gentile (Italy)

88. TREATING STABLE ACRAL VITILIGO BY AUTOMATED MICRONEEDLING AND TOPICAL 5-FLUOROURACIL SOLUTION
Hasan El-Fakahany, Walid Medhat, Hamza Abdel-Raouf (Egypt)

89. KERATINOCYTES DRIVE THE PROGRESSION OF VITILIGO THROUGH CHEMOKINE PRODUCTION AND POSITIONING OF AUTOREACTIVE T CELLS IN THE EPIDERMIS
John Harris, Jillian Richmond, Michele Youd, Kingsley Essien, Sharif Currimbhoy, Andrew Luster, Amit Pandya (MA, TX United States)

90. AUTOLOGOUS CELL SUSPENSION GRAFTING IN SEGMENTAL VITILIGO AND PIEBALDISM: A RANDOMIZED CONTROLLED TRIAL ON THE RECIPIENT SITE PREPARATION
Annelies Lommerts, Arne Meesters, Lisa Komen, Marcel Bekkenk, Menno de Rie, Rosalie Luiten, Albert Wolkerstorfer (The Netherlands)

91. CHEMICAL PEELING WITH TRICHLOROACETIC ACID 25% FOR THE TREATMENT OF VITILIGO: A RANDOMIZED CONTROLLED CLINICAL TRIAL
Heba Mashaly, Medhat El Mofty, Wedad Mostafa, Rehab Hegazy, Marwa El Hawary (Egypt)
Session 7 - Clinical reports

96. **TWO CASES OF VITILIGO LIKE DEPIGMENTATION (VLD) ASSOCIATED WITH MALIGNANT MELANOMA MM: COULD DISTINCTIVE CLINICAL AND HISTOLOGICAL CHARACTERS BE ISOLATED?**
   Laila Benzekri, Yvon Gauthier (Morocco)

97. **NEW TRENDS IN RATOKDERM METHODOLOGY FOR TREATMENT OF VITILIGO**
   Fantato Marina, Cammisa Anna (Italy)

98. **EPIDERMAL SKIN GRAFTING IN VITILIGO**
   Agata Janowska, Valentina Dini, Teresa Oranges, Salvatore Panduri, Marco Romanelli (Italy)

100. **EFFICACY OF MICRONEEDLING WITH TOPICAL VITAMIN C IN TREATMENT OF MELASMA**
   Essameldin Nada, Wafaa Abdel-Magid, Esraa Lsmail (Egypt)

101. **CEREBROSIDES ROLE AND CONTENT OF THE SKIN IN PATIENTS WITH VITILIGO**
   Botir Saatov (Uzbekistan)

102. **DISTURBANCE OF MELANOGENESIS AND MELANOSOME TRANSFER ON THE LEUKODERMA LESION IN EXTRA-MAMMARY PAGET’S DISEASE**
   Atsushi Tanemura, Aya Tanaka, St Fei Yang, Mari-Wataya Kaneda, Ichiro Katayama, Naoki Oiso (Japan)

103. **USE OF A NEW KIT FOR EPIDERMAL CELL SUSPENSION GRAFTING, A MULTICENTRIC PLACEBO CONTROLLED STUDY: PRELIMINARY RESULTS**
   Alessia Pacifico, Andrea Paro Vidolin, Giovanni Leone (Italy)

104. **AN ATYPICAL CASE OF VITILIGO**
   S. Calvieri, E. Moliterni, S. Giustini (Italy)
WITH THE UNCONDITIONED CONTRIBUTION OF

Almirall
Solutions with you in mind

INTEXO

GIULIANI

CERCA DERMATOLOGICA

Pfizer

BIODERMA
LABORATOIRE DERMATOLOGIQUE

abbvie

Laboratoires Genevrier

L E O

Celgene

alida de pase
rehabilitative cosmetics

difa cooper
Skin expert solutions

GALDERMA

BioNike

assoiazione francese de vitiligo